GlassScriptPhysician profile
Tammy L Mccarty
NPI 1407851819
$1,469.79
in general payments reported to CMS, 2019-2025
25 companies · $936 in 2025
The $936 reported for 2025 was more than what 88% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.70 · 2023: $22.38 · 2024: $430 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.59 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $234.58 | 2024-2025 | |
| Sequel Med Tech, LLC | $184.66 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $127.43 | 2024-2025 | Ultomiris, Strensiq |
| Tandem Diabetes Care, INC. | $127.02 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $108.47 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Soleno Therapeutics, INC. | $70.33 | 2025 | Vykat Xr |
| Insulet Corporation | $69.04 | 2022-2024 | Omnipod |
| Tolmar, INC. | $63.95 | 2024-2025 | Fensolvi |
| Mannkind Corporation | $57.14 | 2025 | |
| Abbvie INC. | $49.96 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $43.34 | 2025 | |
| Novo Nordisk INC | $40.42 | 2024-2025 | Sogroya |
| Azurity Pharmaceuticals, INC. | $39.51 | 2024-2025 | Triptodur |
| Biomarin Pharmaceutical INC. | $35.89 | 2025 | Voxzogo 1.2mg |
| Calliditas Therapeutics US INC. | $28.49 | 2025 | Tarpeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $27.11 | 2025 | Omnitrope |
| Aurinia Pharma U.S., INC. | $25.27 | 2024 | Lupkynis |
| Leadiant Biosciences, INC. | $22.09 | 2024 | Cystaran |
| Ascendis Pharma Endocrinology INC | $22.07 | 2025 | Skytrofa |
| Xeris Pharmaceuticals, INC. | $19.28 | 2022 | |
| Pfizer INC. | $17.38 | 2025 | |
| Eton Pharmaceuticals, INC. | $15.19 | 2025 | Khindivi, Increlex, Alkindi |
| Lifescan, INC. | $14.95 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $14.14 | 2022 | |
| Zealand Pharma US, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.